US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake of Donald Trump's election for a second term as President.
He added: 'While this approval is a solid win for GSK, it also signals broader optimism for the industry, despite some lingering nerves around pending approvals given the shakeup that's expected under the Trump administration, including layoffs at the FDA.'.
GSK's sales rose by 7 per cent to £31.7billion last year, thanks to increasing demand for HIV treatments and oncology medicines, as well as purchases of its meningitis vaccines by the CDC.
Thumbs up: US regulators have given the green light for Penmenvy, a new meningitis vaccine developed by pharmaceutical giant GSK.
President Donald Trump appointed Robert F Kennedy Jr to run the US Department of Health and Human Services, whose responsibilities include overseeing the FDA and Centers for Disease Control (CDC).
